Latest developments and clinical news on Ritlecitinib

Ritlecitinib (trade name: Litfulo) is an oral JAK3/TEC kinase inhibitor used to treat severe alopecia areata (Alopecia Areata, AA). In 2023 June , the US FDA approved it for use in adults and adolescent patients 12 years old and above, becoming the first drug approved for the treatment of severe alopecia areata in this age group.

In clinical studies, ritexitinib has shown significant efficacy. In the 48weekALLEGRO clinical trial, 50 About 23% of patients taking the mg daily dose achieved more than 80% scalp hair regrowth at 24 weeks, compared with 1.6% in the control group. Long-term use data show that ritexitinib significantly improved patients' SALT scores during 15 months of treatment, especially those with mild baseline hair loss, showing near-complete hair regeneration.

In terms of safety, ritexitinib was generally well tolerated. In the 36 long-term study, 97.4% of patients reported adverse events, of which 6.8% were serious adverse events. Nonetheless, most adverse events were mild or moderate and manageable during treatment.

At present, ritexitinib has been approved in the United States, the European Union, Canada and other regions, and is marketed in many countries. However, it is not yet available in mainland China, and patients must purchase it through overseas channels if they need to use it. With global regulatory agencies recognizing the drug, it is expected that more regions will approve its marketing in the future, providing treatment options for more patients.

Reference materials:https://www.litfulo.com/